{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:14:26Z","timestamp":1771978466834,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Wan Fang Hospital, Taipei Medical University","award":["105MU-WFH-10"],"award-info":[{"award-number":["105MU-WFH-10"]}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology of Taiwan","doi-asserted-by":"crossref","award":["MOST 104-2314-B-075-047"],"award-info":[{"award-number":["MOST 104-2314-B-075-047"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Taiwan Ministry of Science and Technology Academic Excellence Program","award":["MOST 106-2633-B-009-001"],"award-info":[{"award-number":["MOST 106-2633-B-009-001"]}]},{"name":"Ministry of Health and Welfare","award":["MOHW106-TDU-B-211-113001"],"award-info":[{"award-number":["MOHW106-TDU-B-211-113001"]}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V105C-0207"],"award-info":[{"award-number":["V105C-0207"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V106C-045"],"award-info":[{"award-number":["V106C-045"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>While the patency of vascular access is essential for hemodialysis patients, optimal pharmaceutical treatment to maintain arteriovenous fistula (AVF) patency remains lacking. As cardiovascular diseases are highly prevalent in patients with end-stage renal disease, various cardiovascular medications have also been used to maintain AVF patency. However, previous studies revealed inconsistent therapeutic effects and a comprehensive evaluation of this issue is needed. The present retrospective, longitudinal cohort study included patients receiving successful AVF creation. The evaluated cardiovascular medications included antiplatelet agents, antihypertensive agents, nitrates and nitrites, statins, dipyridamole, and pentoxifylline. The outcome was AVF primary patency. All laboratory data and medication profiles were recorded at baseline and followed at 3-month interval, until the end of the 2-year study period. Cox proportional regression model with time-dependent covariates was used to evaluate the risk for AVF patency loss. A total of 349 patients were included in the present study, in which 57% were men and the mean age was 65\u2009\u00b1\u200914\u00a0years. Among the included patients, 40% used antiplatelet agents, 27% used dipyridamole and 36% used statins at baseline. Of all the evaluated cardiovascular medications, only dipyridamole showed significant association with a higher risk for loss of AVF patency. To evaluate the effect of combination of antiplatelet agents and dipyridamole, the patients were classified into four groups, I: combine use of antiplatelet agents and dipyridamole, II: antiplatelet only, III: dipyridamole only; IV: none of both were used. Of the four groups, group IV exhibited highest AVF patency (52.4%), which was followed by group III (42.7%), group II (40%), and group I (28.6%), respectively. Compared with group IV, only group I showed a significantly higher risk for AVF patency loss. None of the cardiovascular medications evaluated in the present study showed a beneficial effect on AVF patency. Furthermore, dipyridamole showed an association with a higher risk of AVF patency loss. We do not suggest a beneficial effect of dipyridamole on maintaining AVF patency, particularly in combination with antiplatelet agents.<\/jats:p>","DOI":"10.1038\/s41598-020-69019-6","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T10:04:54Z","timestamp":1595412294000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effects of cardiovascular medications on primary patency of hemodialysis arteriovenous fistula"],"prefix":"10.1038","volume":"10","author":[{"given":"Te-I.","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Hsien","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Ling","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-You","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Chang","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Shun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuh-Mou","family":"Sue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung-Ho","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-Yen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Ming","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shing-Jong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Hsun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Te","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"69019_CR1","unstructured":"USRDS. Annual Data Report (2018). https:\/\/www.usrds.org\/2018\/view\/Default.aspx. Accessed 11 June 2019."},{"key":"69019_CR2","unstructured":"Annual Report on Kidney Disease in Taiwan (2017). https:\/\/www.tsn.org.tw\/UI\/L\/TWRD\/ebook_2017%E5%B9%B4%E5%A0%B1.pdf. Accessed 11 June 2019."},{"issue":"4","key":"69019_CR3","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1046\/j.1523-1755.2001.00947.x","volume":"60","author":"RK Dhingra","year":"2001","unstructured":"Dhingra, R. K., Young, E. W., Hulbert-Shearon, T. E., Leavey, S. F. & Port, F. K. Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int. 60(4), 1443\u20131451 (2001).","journal-title":"Kidney Int."},{"issue":"1","key":"69019_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/112972980800900108","volume":"9","author":"M Field","year":"2008","unstructured":"Field, M. et al. Primary patency rates of AV fistulas and the effect of patient variables. J. Vasc. Access. 9(1), 45\u201350 (2008).","journal-title":"J. Vasc. Access."},{"issue":"3","key":"69019_CR5","doi-asserted-by":"publisher","first-page":"714","DOI":"10.2215\/CJN.02950707","volume":"3","author":"HJ Huijbregts","year":"2008","unstructured":"Huijbregts, H. J. et al. Hemodialysis arteriovenous fistula patency revisited: Results of a prospective, multicenter initiative. Clin. J. Am. Soc. Nephrol. 3(3), 714\u2013719 (2008).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"69019_CR6","volume-title":"Vascular Access Surgery\u2014Tips and Tricks","author":"H Rebecca","year":"2018","unstructured":"Rebecca, H., David, J. & Andrea, V. Pathogenesis and prevention of vascular access failure. In Vascular Access Surgery\u2014Tips and Tricks (ed. Alexander, E. B.) (IntechOpen, London, 2018)."},{"issue":"7","key":"69019_CR7","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/BF01468835","volume":"52","author":"K Andrassy","year":"1974","unstructured":"Andrassy, K. et al. Prevention of p.o. clotting of a.v. cimino fistulae with acetylsalicyl acid. Results of a prospective double-blind study. Klin Wochenschr. 52(7), 348\u2013349 (1974).","journal-title":"Klin Wochenschr."},{"issue":"2","key":"69019_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4103\/0971-4065.53323","volume":"19","author":"A Ghorbani","year":"2009","unstructured":"Ghorbani, A., Aalamshah, M., Shahbazian, H., Ehsanpour, A. & Aref, A. Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian J. Nephrol. 19(2), 57\u201361 (2009).","journal-title":"Indian J. Nephrol."},{"issue":"18","key":"69019_CR9","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1001\/jama.299.18.2164","volume":"299","author":"LM Dember","year":"2008","unstructured":"Dember, L. M. et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: A randomized controlled trial. JAMA 299(18), 2164\u20132171 (2008).","journal-title":"JAMA"},{"issue":"1","key":"69019_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/00365598509180223","volume":"19","author":"KC Gr\u00f6ntoft","year":"1985","unstructured":"Gr\u00f6ntoft, K. C., Mulec, H., Gutierrez, A. & Olander, R. Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scand. J. Urol. Nephrol. 19(1), 55\u201357 (1985).","journal-title":"Scand. J. Urol. Nephrol."},{"issue":"1","key":"69019_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1525-1594.1985.tb04349.x","volume":"9","author":"CE Fiskerstrand","year":"1985","unstructured":"Fiskerstrand, C. E., Thompson, I. W., Burnet, M. E., Williams, P. & Anderton, J. L. Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis. Artif. Organs 9(1), 61\u201363 (1985).","journal-title":"Artif. Organs"},{"issue":"4","key":"69019_CR12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.avsg.2008.08.033","volume":"23","author":"M Righetti","year":"2009","unstructured":"Righetti, M., Ferrario, G., Serbelloni, P., Milani, S. & Tommasi, A. Some old drugs improve late primary patency rate of native arteriovenous fistulas in hemodialysis patients. Ann. Vasc. Surg. 23(4), 491\u2013497 (2009).","journal-title":"Ann. Vasc. Surg."},{"issue":"6","key":"69019_CR13","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/j.jvs.2011.06.028","volume":"54","author":"RS Jackson","year":"2011","unstructured":"Jackson, R. S., Sidawy, A. N., Amdur, R. L., Khetarpal, A. & Macsata, R. A. Angiotensin receptor blockers and antiplatelet agents are associated with improved primary patency after arteriovenous hemodialysis access placement. J. Vasc. Surg. 54(6), 1706\u20131712 (2011).","journal-title":"J. Vasc. Surg."},{"issue":"6","key":"69019_CR14","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1053\/ajkd.2002.36895","volume":"40","author":"R Saran","year":"2002","unstructured":"Saran, R. et al. Association between vascular access failure and the use of specific drugs: The dialysis outcomes and practice patterns study (DOPPS). Am. J. Kidney Dis. 40(6), 1255\u20131263 (2002).","journal-title":"Am. J. Kidney Dis."},{"issue":"11","key":"69019_CR15","doi-asserted-by":"publisher","first-page":"e0166362","DOI":"10.1371\/journal.pone.0166362","volume":"11","author":"FA Chen","year":"2016","unstructured":"Chen, F. A., Chien, C. C., Chen, Y. W., Wu, Y. T. & Lin, C. C. Angiotensin converting-enzyme inhibitors, angiotensin receptor blockers, and calcium channel blockers are associated with prolonged vascular access patency in uremic patients undergoing hemodialysis. PLoS ONE 11(11), e0166362 (2016).","journal-title":"PLoS ONE"},{"issue":"3","key":"69019_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1046\/j.1525-139X.2001.00043.x","volume":"14","author":"DA Goodkin","year":"2001","unstructured":"Goodkin, D. A., Mapes, D. L. & Held, P. J. The dialysis outcomes and practice patterns study (DOPPS): How can we improve the care of hemodialysis patients?. Semin. Dial. 14(3), 157\u2013159 (2001).","journal-title":"Semin. Dial."},{"issue":"2","key":"69019_CR17","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamainternmed.2016.8029","volume":"177","author":"AB Irish","year":"2017","unstructured":"Irish, A. B. et al. Effect of fish oil supplementation and aspirin use on Arteriovenous fistula failure in patients requiring hemodialysis: A randomized clinical trial. JAMA Intern. Med. 177(2), 184\u2013193 (2017).","journal-title":"JAMA Intern. Med."},{"issue":"4","key":"69019_CR18","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1080\/003655998750015458","volume":"32","author":"KC Gr\u00f6ntoft","year":"1998","unstructured":"Gr\u00f6ntoft, K. C., Larsson, R., Mulec, H., Weiss, L. G. & Dickinson, J. P. Effects of ticlopidine in AV-fistula surgery in uremia. Fistula study group. Scand. J. Urol. Nephrol. 32(4), 276\u2013283 (1998).","journal-title":"Scand. J. Urol. Nephrol."},{"issue":"4","key":"69019_CR19","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1542-4758.2012.00762.x","volume":"17","author":"N Birch","year":"2013","unstructured":"Birch, N., Fillaus, J. & Florescu, M. C. The effect of statin therapy on the formation of arteriovenous fistula stenoses and the rate of reoccurrence of previously treated stenoses. Hemodial Int. 17(4), 586\u2013593 (2013).","journal-title":"Hemodial Int."},{"issue":"5","key":"69019_CR20","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1093\/ndt\/gfl821","volume":"22","author":"A Sajgure","year":"2007","unstructured":"Sajgure, A., Choudhury, A., Ahmed, Z. & Choudhury, D. Angiotensin converting enzyme inhibitors maintain polytetrafluoroethylene graft patency. Nephrol. Dial Transplant. 22(5), 1390\u20131398 (2007).","journal-title":"Nephrol. Dial Transplant."},{"issue":"Suppl 2","key":"69019_CR21","first-page":"88","volume":"22","author":"J Tordoir","year":"2007","unstructured":"Tordoir, J. et al. EBPG on vascular access. Nephrol. Dial Transplant. 22(Suppl 2), 88\u2013117 (2007).","journal-title":"Nephrol. Dial Transplant."},{"issue":"5","key":"69019_CR22","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1525-139X.2011.00969.x","volume":"24","author":"T Lee","year":"2011","unstructured":"Lee, T. et al. Standardized definitions for hemodialysis vascular access. Semin. Dial. 24(5), 515\u2013524 (2011).","journal-title":"Semin. Dial."},{"issue":"3","key":"69019_CR23","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1067\/mva.2002.122025","volume":"35","author":"AN Sidawy","year":"2002","unstructured":"Sidawy, A. N. et al. Recommended standards for reports dealing with arteriovenous hemodialysis accesses. J. Vasc. Surg. 35(3), 603\u2013610 (2002).","journal-title":"J. Vasc. Surg."},{"issue":"5","key":"69019_CR24","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1053\/j.ajkd.2007.07.019","volume":"50","author":"P Roy-Chaudhury","year":"2007","unstructured":"Roy-Chaudhury, P. et al. Neointimal hyperplasia in early arteriovenous fistula failure. Am. J. Kidney Dis. 50(5), 782\u2013790 (2007).","journal-title":"Am. J. Kidney Dis."},{"issue":"10","key":"69019_CR25","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1681\/ASN.2016121355","volume":"28","author":"AK Cheung","year":"2017","unstructured":"Cheung, A. K. et al. Hemodialysis fistula maturation study group. Intimal hyperplasia, stenosis, and arteriovenous fistula maturation failure in the hemodialysis fistula maturation study. J. Am. Soc. Nephrol. 28(10), 3005\u20133013 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"10","key":"69019_CR26","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.2215\/CJN.02740313","volume":"8","author":"M Allon","year":"2013","unstructured":"Allon, M. et al. Preoperative venous intimal hyperplasia, postoperative arteriovenous fistula stenosis, and clinical fistula outcomes. Clin. J. Am. Soc. Nephrol. 8(10), 1750\u20131755 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"3","key":"69019_CR27","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1053\/j.ajkd.2016.02.044","volume":"68","author":"M Tabbara","year":"2016","unstructured":"Tabbara, M. et al. Pre-existing and postoperative intimal hyperplasia and arteriovenous fistula outcomes. Am. J. Kidney Dis. 68(3), 455\u2013464 (2016).","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"69019_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1053\/j.ajkd.2018.12.035","volume":"74","author":"L Martinez","year":"2019","unstructured":"Martinez, L. et al. Transcriptomics of human arteriovenous fistula failure: Genes associated with nonmaturation. Am. J. Kidney Dis. 74(1), 73\u201381 (2019).","journal-title":"Am. J. Kidney Dis."},{"issue":"3","key":"69019_CR29","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1681\/ASN.2017050559","volume":"29","author":"L Martinez","year":"2018","unstructured":"Martinez, L. et al. Fibrotic venous remodeling and nonmaturation of arteriovenous fistulas. J. Am. Soc. Nephrol. 29(3), 1030\u20131040 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"69019_CR30","doi-asserted-by":"publisher","first-page":"e0119958","DOI":"10.1371\/journal.pone.0119958","volume":"10","author":"K Bashar","year":"2015","unstructured":"Bashar, K. et al. Predictive parameters of arteriovenous fistula functional maturation in a population of patients with end-stage renal disease. PLoS ONE 10(3), e0119958 (2015).","journal-title":"PLoS ONE"},{"issue":"1","key":"69019_CR31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12882-018-1010-6","volume":"19","author":"CC Yen","year":"2018","unstructured":"Yen, C. C. et al. Factors affecting fistula failure in patients on chronic hemodialysis: A population-based case-control study. BMC Nephrol. 19(1), 213 (2018).","journal-title":"BMC Nephrol."},{"issue":"5","key":"69019_CR32","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.avsg.2011.09.014","volume":"26","author":"M Fokou","year":"2012","unstructured":"Fokou, M. et al. Complications of arteriovenous fistula for hemodialysis: An 8-year study. Ann. Vasc. Surg. 26(5), 680\u2013684 (2012).","journal-title":"Ann. Vasc. Surg."},{"issue":"1","key":"69019_CR33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1159\/000491828","volume":"48","author":"K Wang","year":"2018","unstructured":"Wang, K. et al. Effect of anti-hypertensive medication history on arteriovenous fistula maturation outcomes. Am. J. Nephrol. 48(1), 56\u201364 (2018).","journal-title":"Am. J. Nephrol."},{"key":"69019_CR34","doi-asserted-by":"publisher","first-page":"22197","DOI":"10.1038\/srep22197","volume":"6","author":"HH Chang","year":"2016","unstructured":"Chang, H. H. et al. Statins improve long term patency of arteriovenous fistula for hemodialysis. Sci. Rep. 6, 22197 (2016).","journal-title":"Sci. Rep."},{"issue":"6","key":"69019_CR35","doi-asserted-by":"publisher","first-page":"471","DOI":"10.5301\/jva.5000612","volume":"17","author":"L Martinez","year":"2016","unstructured":"Martinez, L. et al. Distinct impact of three different statins on arteriovenous fistula outcomes: A retrospective analysis. J. Vasc. Access. 17(6), 471\u2013476 (2016).","journal-title":"J. Vasc. Access."},{"issue":"5","key":"69019_CR36","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/ki.1994.192","volume":"45","author":"R Sreedhara","year":"1994","unstructured":"Sreedhara, R., Himmelfarb, J., Lazarus, J. M. & Hakim, R. M. Anti-platelet therapy in graft thrombosis: Results of a prospective, randomized. Double-blind study. Kidney Int. 45(5), 1477\u20131483 (1994).","journal-title":"Kidney Int."},{"issue":"21","key":"69019_CR37","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa0805840","volume":"360","author":"BS Dixon","year":"2009","unstructured":"Dixon, B. S. et al. DAC Study Group. Effect of dipyridamole plus aspirin on hemodialysis graft patency. N. Engl. J. Med. 360(21), 2191\u20132201 (2009).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"69019_CR38","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1503\/cmaj.050871","volume":"173","author":"C Sudlow","year":"2005","unstructured":"Sudlow, C. What is the role of dipyridamole in long-term secondary prevention after an ischemic stroke or transient ischemic attack?. CMAJ 173(9), 1024\u20131026 (2005).","journal-title":"CMAJ"},{"issue":"2","key":"69019_CR39","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1111\/jcmm.14006","volume":"23","author":"Q Yan","year":"2019","unstructured":"Yan, Q. et al. The signal pathway for the repressive effect of dipyridamole on myofibroblast transdifferentiation. J. Cell Mol. Med. 23(2), 1608\u20131612 (2019).","journal-title":"J. Cell Mol. Med."},{"issue":"6","key":"69019_CR40","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/j.1742-7843.2006.pto_516.x","volume":"99","author":"SB Zhuplatov","year":"2006","unstructured":"Zhuplatov, S. B., Masaki, T., Blumenthal, D. K. & Cheung, A. K. Mechanism of dipyridamole\u2019s action in inhibition of venous and arterial smooth muscle cell proliferation. Basic Clin. Pharmacol. Toxicol. 99(6), 431\u2013439 (2006).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"7","key":"69019_CR41","first-page":"CD002786","volume":"2015","author":"NC Tanner","year":"2015","unstructured":"Tanner, N. C. & Silva, A. D. Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database Syst Rev. 2015(7), CD002786 (2015).","journal-title":"Cochrane Database Syst Rev."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69019-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69019-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69019-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T17:11:36Z","timestamp":1696439496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69019-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["69019"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-69019-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,22]]},"assertion":[{"value":"23 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12135"}}